




Healthcare Industry News: Topiramate
News Release - December 24, 2013
Supernus Announces Resignation of Board Member
ROCKVILLE, Md., Dec. 24, 2013 -- (Healthcare Sales & Marketing Network) -- Supernus Pharmaceuticals, Inc. (SUPN), a specialty pharmaceutical company, announced today that Michael Bigham, a General Partner at Abingworth has resigned from the company's board of directors, effective December 23, 2013.About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The Company has two marketed products for epilepsy, Oxtellar XR(R) (extended-release oxcarbazepine) and Trokendi XR(TM) (extended-release Topiramate). The Company is also developing several product candidates in psychiatry to address large market opportunities in ADHD, including ADHD patients with impulsive aggression. These product candidates include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.
Source: Supernus Pharmaceuticals
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.